Page 3 - reflections_newsletter_June8_2022
P. 3
REFLECTIONS dae mia
Dyslipidaemia Global Newsletter #2 Dyslipi
Dyslipi
aim ead
*Fenofibrate is the preferred fibric acid derivative due to better safety profile and fewer drug interactions compared to gemfibrozil.
CLINICAL PEARLS FROM THE FACULTY Similar detailed algorithms of clinical workflow are provided for
each individual patient scenario.
Management of hypertriglyceridaemia has a key role in
cardiovascular disease prevention. Hence it is crucial to spread
awareness on this topic in order to improve cardiovascular health.
CLICK HERE
FOR THE LINK TO FULL ARTICLE
WATCH
PROF. LAVALLE COBO’S THOUGHTS
ON ACC 2021 RECOMMENDATIONS.
Coronary atherosclerotic plaque regression: JACC state-of-the-art review.
Dawson LP, et al. J Am Coll Cardiol. 2022 Jan 4;79(1):66-82.
The natural history of atherosclerosis is generally progression, which may be complicated by events such as plaque rupture or
erosion. Plaque progression precedes cardiovascular events. Plaque regression may occur as a result of a reduction in plaque lipid
content, macrophage content, and inflammatory state. Improvement in coronary imaging modalities now allow direct assessment of
plaque modification.
This state-of-the-art review focuses on the novel treatment strategies that may induce atherosclerotic plaque regression and the
imaging modalities that can assess modifications in plaque volumes and composition.
TABLE OF CONTENTS Learn more at: www.serviercardiomedicalhub.com
